Method and composition for administering an NMDA receptor antagonist to a subject
First Claim
Patent Images
1. A method of administering memantine to a human subject in need thereof, comprising:
- orally administering to the subject once per day over multiple days a sustained release oral dosage form comprising memantine or a pharmaceutically acceptable salt thereof and a component that sustains release of the memantine or the salt thereof;
wherein a daily dose of 12.5 to 40 mg of memantine or pharmaceutically acceptable salt thereof is administered from the initiation of therapy without prior dose escalation of memantine;
wherein such administration results in the subject achieving a therapeutically effective steady state memantine plasma concentration within 20 days after initiation of therapy with said dosage form; and
wherein the subject has a condition selected from the group consisting of Alzheimer'"'"'s disease, dementia, Parkinson'"'"'s disease and neuropathic pain.
8 Assignments
0 Petitions
Accused Products
Abstract
The invention provides methods and compositions for administering an NMDA receptor antagonist (e.g., memantine) to a subject.
152 Citations
10 Claims
-
1. A method of administering memantine to a human subject in need thereof, comprising:
-
orally administering to the subject once per day over multiple days a sustained release oral dosage form comprising memantine or a pharmaceutically acceptable salt thereof and a component that sustains release of the memantine or the salt thereof; wherein a daily dose of 12.5 to 40 mg of memantine or pharmaceutically acceptable salt thereof is administered from the initiation of therapy without prior dose escalation of memantine; wherein such administration results in the subject achieving a therapeutically effective steady state memantine plasma concentration within 20 days after initiation of therapy with said dosage form; and wherein the subject has a condition selected from the group consisting of Alzheimer'"'"'s disease, dementia, Parkinson'"'"'s disease and neuropathic pain. - View Dependent Claims (2, 3, 4, 5)
-
-
6. A method of administering memantine to a human subject in need thereof, comprising:
-
orally administering to the subject once per day over multiple days a sustained release oral dosage form comprising memantine or a pharmaceutically acceptable salt thereof and a component that sustains release of the memantine or the salt thereof; wherein 12.5 to 40 mg of memantine or pharmaceutically acceptable salt thereof is administered daily from the initiation of therapy without prior dose escalation of memantine; wherein daily administration of 12.5 to 40 mg of memantine or pharmaceutically acceptable salt thereof results in the subject achieving a therapeutically effective steady state memantine plasma concentration within 20 days after initiation of therapy with said dosage form; and wherein the subject has a condition selected from the group consisting of Alzheimer'"'"'s disease, dementia, Parkinson'"'"'s disease and neuropathic pain. - View Dependent Claims (7, 8, 9, 10)
-
Specification